摘要
目的:探讨α-甲酰-CoA消旋酶(AMACR/p504S)在乳腺癌中的表达状况及其临床病理意义。方法:选取73例乳腺癌及36例乳腺良性增生性病变,用免疫组化技术(S-P法)标记AMACR和ER、PR、c-erbB-2,光镜观察其表达情况并进行统计学处理。结果:AMACR在乳腺癌中表达的阳性率为86.3%,良性病变中为55.6%,两者差异有统计学意义(P<0.01)。AMACR在乳腺癌中的表达与组织学类型、分级以及ER、PR、c-erbB-2免疫表型等均无明显关系(P>0.05)。结论:AMACR不仅是前列腺癌的生物学标记,亦可作为乳腺癌病理诊断的参考。
Objective：To investigate the expression of alpha-methylacyl-CoA-racemase（AMACR） in breast cancer and its clinieopathological significance. Methods：AMACR and ER, PR, C-erbB-2 were detected in 73 eases of breast cancer and 36 cases of benign mammary lesions using immunohistochemical technique （ S-P method） , and the results were studied microscopically and statistically. Results：The positive rates of AMACR were 86.3% in breast cancer and 55.6% in benign mammary lesions, which had statistical significance（ P 〈0.01 ）. The expression of AMACR in breast cancer showed no difference among the typing, grading,and ER, PR, C- erbB-2 immunoplenotypes（ P 〉 0.05 ）. Conclusions：AMACR is not only the biomarker of prostate cancer but can also be used in the pathological diagnosis of breast cancer.
出处
《蚌埠医学院学报》
CAS
2009年第4期284-286,共3页
Journal of Bengbu Medical College
基金
安徽省教育厅自然科学研究计划项目(2004kj277)
